→ USPTO

2001/012

PTO/SB/21 (09-04)

JUL 2 6 2006

Approved for use through 07/31/2006, OMB 6651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number. Under the Pagenwork Reduction Act of 1995 no persons are required to respond to a call Application Number 10/663,506 Filing Date **TRANSMITTAL** September 15, 2003 First Named Inventor FORM Ashraf Art Unit 1817 Examiner Name Carter, K (to be used for all correspondence after initial filling) Attorney Docket Number AM-101106US Total Number of Pages In This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Appeal Communication to Board Licensing-related Papers of Appeals and interferences Fee Attached Appeal Communication to TC (Appeal Notice, Brief, Reply Erief) ablaPetition Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please identify Terminal Disclaimer below): Extension of Time Request Request for Refund Express Abandonment Request CD. Number of CD(s) Information Disclosure Statement Lendscape Table on CD Remarks Certified Copy of Priority Document(s) Customer No. 38199 Reply to Missing Perts/ incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name HOWSON AND HOWSON Signature Printed name Cathy A. Kodroff Reg. No. Dale 33,980 26-2006 CERTIFICATE OF TRANSMISSION/MAILING I hereby cartify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date -26-06 J. Jason Galvez Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confinentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form analytic euggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

RECEIVED **CENTRAL FAX CENTER**

JUL 2 6 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/663,506

Confirmation No.: 1850

Applicant

: Ashraf et al.

Filed

: September 15, 2003

TC/A.U.

: 1617

Examiner

. Carter, K

Customer No.: 38199

Title

: SOLID ORAL FORMULATIONS OF RAPAMYCIN 42-ESTER WITH

3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPIONIC

ACID

Commissioner for Patents Mail Stop Amendment P.O. Box 1450 Alexandria, VA 22313-1450

RESPONSE AND AMENDMENDT

Sir:

In timely response to the Office Action dated May 4, 2006, please enter the following response to the claim objections/rejections and amend the above-identified application:

Amendments to the Title begin on 2 of this paper.

Amendments to the Claims are reflected in the listing of claims, which begins on page 3 of this paper.

Remarks/Arguments begin on page 7 of this paper.

US Patent Application No. 10/663,506 Response to OA mail date 5/4/2006 AM-101106US

AMENDMENTS TO THE TITLE

Please replace the title with the following amended title:

ORAL FORMULATIONS-SOLID ORAL FORMULATIONS OF RAPAMYCIN 42-ESTER WITH 3-HYDROXY-2-(HYDROXYMETHYL)-2-METHYLPROPIONIC ACID